End-of-day quote
Shanghai S.E.
18:00:00 2024-05-14 EDT
|
5-day change
|
1st Jan Change
|
36.86
CNY
|
-1.18%
|
|
+5.43%
|
+9.54%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,068
|
11,199
|
19,473
|
18,246
|
22,121
|
24,483
|
-
|
-
|
Enterprise Value (EV)
1 |
9,068
|
11,199
|
19,473
|
18,246
|
22,121
|
24,483
|
24,483
|
24,483
|
P/E ratio
|
17.1
x
|
20.4
x
|
31.4
x
|
26.2
x
|
26.3
x
|
24.2
x
|
20.3
x
|
17
x
|
Yield
|
2.16%
|
1.71%
|
-
|
3.85%
|
3.8%
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.3
x
|
1.7
x
|
-
|
2.21
x
|
2.69
x
|
2.7
x
|
2.46
x
|
2.23
x
|
EV / Revenue
|
1.3
x
|
1.7
x
|
-
|
2.21
x
|
2.69
x
|
2.7
x
|
2.46
x
|
2.23
x
|
EV / EBITDA
|
13.8
x
|
-
|
-
|
16.6
x
|
18
x
|
17.9
x
|
15.1
x
|
12.7
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.98
x
|
2.33
x
|
-
|
3.45
x
|
3.93
x
|
4.15
x
|
3.98
x
|
3.74
x
|
Nbr of stocks (in thousands)
|
768,873
|
773,643
|
773,443
|
773,443
|
770,158
|
770,158
|
-
|
-
|
Reference price
2 |
13.86
|
17.52
|
31.41
|
29.10
|
33.65
|
36.86
|
36.86
|
36.86
|
Announcement Date
|
4/17/20
|
3/30/21
|
3/30/22
|
3/31/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6,994
|
6,604
|
-
|
8,249
|
8,222
|
9,053
|
9,961
|
10,982
|
EBITDA
1 |
657
|
-
|
-
|
1,099
|
1,227
|
1,370
|
1,618
|
1,924
|
EBIT
1 |
555.7
|
785.2
|
-
|
980
|
1,097
|
1,317
|
1,573
|
1,879
|
Operating Margin
|
7.95%
|
11.89%
|
-
|
11.88%
|
13.34%
|
14.55%
|
15.79%
|
17.11%
|
Earnings before Tax (EBT)
1 |
743.1
|
768.1
|
-
|
980.2
|
1,095
|
1,318
|
1,573
|
1,879
|
Net income
1 |
625.6
|
661.7
|
769.1
|
861.8
|
986.7
|
1,173
|
1,399
|
1,672
|
Net margin
|
8.94%
|
10.02%
|
-
|
10.45%
|
12%
|
12.96%
|
14.05%
|
15.23%
|
EPS
2 |
0.8100
|
0.8600
|
1.000
|
1.110
|
1.280
|
1.523
|
1.817
|
2.173
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.3000
|
0.3000
|
-
|
1.120
|
1.280
|
-
|
-
|
-
|
Announcement Date
|
4/17/20
|
3/30/21
|
3/30/22
|
3/31/23
|
3/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
12.1%
|
11.8%
|
-
|
13.2%
|
15.1%
|
17.2%
|
19.7%
|
22.4%
|
ROA (Net income/ Total Assets)
|
8.37%
|
-
|
-
|
-
|
-
|
11.2%
|
13.6%
|
15.4%
|
Assets
1 |
7,474
|
-
|
-
|
-
|
-
|
10,475
|
10,288
|
10,859
|
Book Value Per Share
2 |
7.010
|
7.510
|
-
|
8.430
|
8.570
|
8.890
|
9.270
|
9.860
|
Cash Flow per Share
2 |
0.9500
|
0.8700
|
-
|
0.8800
|
0.8900
|
1.500
|
1.400
|
1.540
|
Capex
1 |
206
|
182
|
-
|
106
|
141
|
30
|
29
|
28
|
Capex / Sales
|
2.94%
|
2.76%
|
-
|
1.29%
|
1.71%
|
0.33%
|
0.29%
|
0.25%
|
Announcement Date
|
4/17/20
|
3/30/21
|
3/30/22
|
3/31/23
|
3/29/24
|
-
|
-
|
-
|
Last Close Price
36.86
CNY Average target price
45.8
CNY Spread / Average Target +24.25% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.54% | 3.39B | | +45.15% | 6.34B | | -14.00% | 4.61B | | -8.99% | 3.29B | | +50.03% | 2.02B | | -6.97% | 1.73B | | -0.31% | 1.67B | | +50.00% | 1.63B | | -10.61% | 1.59B | | +36.19% | 1.34B |
Alternative Medicine
|